There is a question that haunts many couples who have experienced repeated IVF failure — particularly those whose embryos were good, whose uterine lining was adequate, whose sperm DNA was intact, and whose immunological testing was never performed: could my own body be working against me?

It is not an irrational question. And in a meaningful proportion of couples with unexplained repeated IVF failure, it is not merely a question. It is a diagnosis — one that has been present all along, silently preventing implantation cycle after cycle, and never identified because the investigation that would have found it was never performed.

The immune system's role in implantation is one of the most fascinating — and one of the most clinically important — areas of reproductive medicine. It is also one of the most misunderstood, both by patients who have read about it online and by clinicians who are unfamiliar with its nuances. Some immunological conditions are well established as causes of IVF failure and have clearly effective treatments. Others are more controversial — conditions where the association with IVF failure is observed but the optimal treatment remains debated.

This article navigates both categories honestly — explaining the immune mechanisms that are most clearly relevant to IVF failure, the conditions that can be diagnosed and treated, the investigations that identify them, and the important distinction between evidence-based immunological treatment and the more speculative approaches that circulate in fertility forums and social media.

For couples who have failed IVF without a clear explanation, the immune system is one of the most important dimensions of investigation that may not yet have been explored. This article explains why — and what exploring it involves.

Why the Immune System Is Involved in Implantation at All

To understand how the immune system can cause IVF failure, it helps to first understand why the immune system is involved in implantation in the first place — because it is a relationship that is not immediately intuitive.

The immune system's fundamental function is to distinguish self from non-self — to identify foreign material and mount a response against it. This is the mechanism that protects us from infection, from cancer, and from transplanted tissues that carry foreign proteins. And it is precisely this mechanism that creates a paradox in pregnancy.

A human embryo carries genetic material from two sources — the mother and the father. From the mother's immune system's perspective, the embryo is a semi-allograft — an entity that is partly self and partly foreign. Half of the embryo's proteins are paternal in origin and are, immunologically speaking, as foreign as a transplanted organ from a different person. By the logic of immune surveillance, the body should reject the embryo as it would reject any other foreign tissue.

The fact that pregnancy normally proceeds without this rejection occurring — that the maternal immune system tolerates the embryo throughout nine months of development — is not an absence of immune activity. It is an active, precisely regulated process of immune tolerance. The uterus creates a specialized immunological environment in which the embryo is recognized and protected rather than attacked. Specific immune cells — uterine natural killer cells, regulatory T cells, dendritic cells — participate in this environment, facilitating the vascular remodeling necessary for placental development and suppressing the destructive immune responses that would otherwise target the embryo.

When this finely regulated tolerance mechanism fails — when the immune system mounts responses against the embryo rather than protecting it — implantation fails. The embryo, which might be chromosomally normal and morphologically excellent, cannot establish itself in an immunological environment that is actively working against it.

This is the mechanism underlying immunological causes of IVF failure. And it occurs through several distinct pathways — each with its own diagnostic test and its own treatment approach.

Condition One: Antiphospholipid Syndrome — The Most Important and Most Treatable

Antiphospholipid syndrome — APS — is the most clearly established and most clinically important immunological cause of recurrent implantation failure and pregnancy loss. It is also among the most treatable — once identified.

What It Is

APS is an autoimmune condition in which the immune system produces antibodies — antiphospholipid antibodies — that target phospholipids, which are components of cell membranes. These antibodies interfere with the normal function of coagulation factors in a way that promotes abnormal blood clotting — a tendency toward thrombus formation in blood vessels of any size.

In the context of pregnancy and implantation, the relevant vessels are the tiny blood vessels of the developing placenta. The earliest stages of placental development — which begin at the time of implantation — involve the invasion of maternal blood vessels by specialized placental cells called trophoblasts, and the establishment of blood flow from the maternal circulation to the developing placenta. When APS-associated antibodies interfere with this process — promoting clotting in the tiny placental vessels and disrupting normal trophoblast invasion — implantation fails, or the pregnancy establishes briefly but cannot sustain the vascular support it needs and ends in early miscarriage.

How It Is Diagnosed

APS is diagnosed through blood tests that detect the specific antibodies associated with the condition. The three most important are anticardiolipin antibodies — IgG and IgM — anti-beta-2 glycoprotein-1 antibodies — IgG and IgM — and lupus anticoagulant. A diagnosis of APS requires at least one of these antibodies to be present on two separate occasions at least twelve weeks apart — the double-positive criterion — because transient antibody positivity can occur with infection and does not carry the same clinical significance as persistent positivity.

How It Is Treated

APS-associated recurrent implantation failure and pregnancy loss responds well to anticoagulation therapy — specifically the combination of low-dose aspirin, initiated before the embryo transfer, and low-molecular-weight heparin, initiated at the time of or shortly after transfer and continued through the first trimester. This combination prevents the abnormal clotting that disrupts placental blood flow and allows the normal vascular development of early pregnancy to proceed.

The treatment is straightforward, low-risk, and well-tolerated. It requires only daily injections of low-molecular-weight heparin — which most patients manage without difficulty — and a single daily aspirin tablet. The evidence supporting this treatment in APS-confirmed patients is robust, and the improvement in implantation and pregnancy continuation rates in treated patients is substantial.

This is why testing for APS before an IVF retry — specifically in women with recurrent implantation failure or recurrent early pregnancy loss — is one of the most clinically impactful things that can be done. A diagnosis of APS transforms the prognosis from repeated unexplained failure to a treatable condition with excellent outcomes under appropriate anticoagulation.

Condition Two: Thyroid Autoimmunity — The Silent Immunological Saboteur

Thyroid autoimmunity — the presence of thyroid antibodies, specifically anti-thyroid peroxidase antibodies and anti-thyroglobulin antibodies — is found in approximately 10 to 15 percent of women of reproductive age. It is the most common autoimmune condition associated with infertility and pregnancy loss, and it is one of the most frequently missed because it can be present in women with entirely normal thyroid function — normal TSH, normal T3, normal T4.

The thyroid-related question that most clinics answer is: is this woman's thyroid function normal? The question that should also be asked — and that most clinics do not ask — is: does this woman have thyroid antibodies, and if so, how are they affecting her reproductive outcomes?

The Mechanism

Thyroid antibodies are associated with reduced implantation rates and higher miscarriage rates through several mechanisms that are not yet fully characterized but are consistently observed across a substantial body of clinical research. Thyroid antibodies may affect the local immunological environment of the endometrium, may be associated with more broadly dysregulated immune function that compromises tolerance of the embryo, and in some cases may directly affect trophoblast function — the function of the placental cells that are critical to implantation.

Testing and Treatment

Testing for thyroid antibodies requires a specific blood test — anti-TPO and anti-TG antibody levels — that is separate from standard thyroid function testing and is not performed in routine blood work at most clinics.

When thyroid antibodies are found in women with recurrent implantation failure or recurrent miscarriage, several management approaches are considered. Optimization of thyroid function to a TSH below 2.5 mIU/L — rather than the general normal range threshold — is the first step, and is warranted even in women with antibodies whose TSH is in the general normal range. In some cases, low-dose levothyroxine supplementation is used to achieve this optimization and to reduce the autoimmune burden on thyroid function. Selenium supplementation has a documented evidence base for reducing thyroid antibody levels over several months and improving thyroid function in women with autoimmune thyroid disease.

Condition Three: Uterine Natural Killer Cell Abnormalities — Genuine but Controversial

Uterine natural killer cells — uNK cells — are the most abundant immune cells in the endometrium during the implantation window, comprising approximately 70 percent of all immune cells in the uterine lining at this time. Their role in implantation is complex and still being characterized — they are not simple destructive cells, as their name might suggest, but are critical facilitators of the vascular remodeling necessary for placental development.

This is the area of reproductive immunology that generates the most discussion — and the most controversy — and it is worth addressing with the honesty that the evidence demands.

What the Evidence Shows

Abnormalities in uNK cell numbers or function — either elevated uNK cell density or dysregulated uNK cell activity — have been associated with recurrent implantation failure in a number of studies. The hypothesis is that elevated or aberrantly activated uNK cells may mount a response against the implanting embryo that disrupts the normal tolerance mechanism, preventing implantation or causing early pregnancy loss.

The association between elevated uNK cells and recurrent implantation failure has been observed in multiple studies and is accepted as a genuine clinical finding in a proportion of affected women. Where the evidence becomes more contested is in the treatment — specifically, whether interventions designed to modulate uNK cell activity reliably improve IVF outcomes in affected women.

Testing

uNK cell assessment requires an endometrial biopsy — a small sample of endometrial tissue taken in the cycle before the planned transfer — which is then examined by immunohistochemistry to quantify the density of CD56-positive natural killer cells. This test is available at specialist laboratories and is offered at Metro IVF in the context of comprehensive immunological evaluation of patients with unexplained recurrent implantation failure.

Treatment and the Importance of Honesty

Treatments proposed for elevated uNK cells include prednisolone — a corticosteroid used to suppress immune activity — intravenous immunoglobulin — IVIg — and intralipid infusion. Of these, intralipid — a fat emulsion administered intravenously that is hypothesized to modulate natural killer cell activity — is the most commonly used in clinical practice, partly because it is lower-cost and lower-risk than IVIg.

The honest position on uNK cell treatment — which Dr. Soni maintains with every patient for whom this investigation is discussed — is that the evidence base is suggestive but not conclusive. The studies supporting treatment are real but not uniformly high-quality, and controlled trials showing clear benefit are still limited. This does not mean that treatment is not warranted in selected patients with documented elevated uNK cells and no other identified cause of failure. It means that the treatment should be offered with appropriate acknowledgment of the uncertainty — not as an established cure but as a reasonable clinical intervention in a carefully selected patient group, with monitoring of outcomes.

Patients who find clinics online claiming that uNK cell treatment is the definitive solution to all unexplained IVF failure should approach those claims with caution. The reality is more nuanced — and more honest — than that.

Condition Four: Inherited Thrombophilias — Clotting Disorders That Compromise Implantation

Beyond antiphospholipid syndrome, inherited conditions that increase blood clotting tendency — thrombophilias — can compromise the vascular development necessary for implantation in similar ways to APS, through different genetic mechanisms.

The Most Clinically Relevant Inherited Thrombophilias

Factor V Leiden mutation — the most common inherited thrombophilia — is a genetic variant that causes resistance to activated protein C, a natural anticoagulant. In its heterozygous form it increases clotting risk moderately. In its homozygous form the risk is substantially higher. Its association with recurrent pregnancy loss is well documented, though its association with implantation failure without pregnancy loss is less clear.

Prothrombin gene mutation — specifically the G20210A variant — is associated with elevated prothrombin levels and increased thrombin generation, promoting clot formation. Like Factor V Leiden, it is associated with recurrent pregnancy loss.

Protein C deficiency, protein S deficiency, and antithrombin III deficiency are rarer inherited conditions that reduce the function of natural anticoagulant proteins, increasing clotting tendency in a similar clinical direction.

MTHFR polymorphisms — variants in the methylenetetrahydrofolate reductase gene — affect folate metabolism and are associated with elevated homocysteine levels, which have prothrombotic and potentially embryotoxic effects. The clinical significance of MTHFR variants in isolation is a subject of ongoing discussion — they are common in the general population and their independent contribution to IVF failure, separate from other thrombophilic conditions, is debated.

Testing and Treatment

Thrombophilia screening requires specific blood tests — genetic testing for Factor V Leiden, prothrombin gene mutation, and MTHFR variants, and functional assays for protein C, protein S, and antithrombin III. These tests are not part of standard pre-IVF work-ups at most clinics.

When inherited thrombophilias are identified in women with recurrent implantation failure or pregnancy loss, anticoagulation therapy — low-molecular-weight heparin with or without aspirin — is typically recommended during the transfer and early pregnancy period. Folate supplementation — at higher doses than standard prenatal supplementation — is recommended for women with MTHFR variants.

Condition Five: Broader Immune Dysregulation — The Emerging Frontier

Beyond the specific conditions described above, there is growing clinical and research interest in broader patterns of immune dysregulation that may contribute to implantation failure — elevated inflammatory cytokines, dysregulated T helper cell balance, abnormal dendritic cell function, and other aspects of the complex immunological environment of the endometrium that are only beginning to be characterized.

These areas represent the frontier of reproductive immunology — genuinely interesting and clinically potentially important, but with an evidence base that is still developing. At Metro IVF, investigations into these areas are conducted where the clinical history and the findings of established immunological testing suggest that broader immune dysregulation may be contributing to unexplained failure — but they are always offered with transparent communication about the state of the evidence and the current limits of what can be confidently concluded.

The immunological assessment of a patient with unexplained recurrent implantation failure at Metro IVF does not stop at a basic panel and declare the investigation complete. But it also does not recommend unproven treatments on the basis of speculative mechanisms. The balance — between thorough investigation and honest acknowledgment of what the evidence does and does not support — is the clinical standard Dr. Soni maintains in every immunological evaluation.

Who Should Have Immunological Testing — and What It Involves

Immunological testing for IVF failure is most strongly indicated in women with two or more failed transfers despite good embryos and adequate endometrial preparation, women with recurrent early pregnancy loss — positive blood test or fetal heartbeat confirmed, followed by miscarriage — women with any personal or family history of autoimmune conditions or clotting disorders, and women in whom ERA, hysteroscopy, sperm DNA fragmentation, and endometrial biopsy have not revealed a satisfying explanation for failure.

The testing at Metro IVF covers the complete immunological and thrombophilia panel described in this article — antiphospholipid antibodies, lupus anticoagulant, thyroid antibodies, inherited thrombophilia screen, and uNK cell assessment where indicated. Blood testing is performed in an appropriately timed fashion — antiphospholipid antibodies confirmed on two separate occasions twelve weeks apart for definitive APS diagnosis, thrombophilia testing performed outside of any anticoagulation therapy.

The results are reviewed in the context of the complete clinical history and interpreted by Dr. Soni with full acknowledgment of what each finding means — and what the evidence supports in terms of treatment.

The Honest Bottom Line

The immune system is a real and clinically important cause of IVF failure — in specific, identifiable, testable conditions that have effective treatments. Antiphospholipid syndrome is the clearest example — a condition that is found in a meaningful proportion of women with recurrent implantation failure and pregnancy loss, that is diagnosed through straightforward blood testing, and that responds excellently to anticoagulation therapy.

Thyroid autoimmunity, inherited thrombophilias, and uNK cell abnormalities are genuinely associated with reproductive failure and warrant investigation in appropriate patients — with treatments that are evidence-informed and offered with appropriate transparency about the strength of the evidence.

The immune system is not, however, the universal explanation for all unexplained IVF failure that some online resources suggest. Not every woman with repeated failure has an immune problem. Not every positive antibody test requires aggressive immune suppression. And not every treatment promoted as targeting the immune system is supported by the quality of evidence that should precede clinical recommendation.

The difference between evidence-based immunological management and speculation — dressed in the same clinical language — matters enormously for couples who are already vulnerable and who deserve the most honest and rigorous guidance available.

At Metro IVF, that distinction is never blurred.

Your Next Step

If you have experienced repeated IVF failure without a clear explanation — and if immunological testing has not been part of your investigation — the assessment described in this article may reveal the cause that has been present all along.

At Metro IVF in Ambikapur, Dr. Ashish Soni conducts a comprehensive immunological evaluation as a standard component of the re-evaluation of every patient with unexplained recurrent implantation failure. The testing is specific, the interpretation is honest, and the treatment recommended is grounded in the best available evidence — not in speculation, not in the latest social media discussion, and not in a commercial interest in recommending treatments regardless of whether they are indicated.

If your body has been working against your embryo — there is a way to find out. And if it has, there is a way to address it.

Metro IVF Test Tube Baby Center Ambikapur, Chhattisgarh metrofertility.in Led by Dr. Ashish Soni — North India's First Fertility Super Specialist

Repeated IVF failure without explanation? The immune system may be the missing piece. Book your immunological evaluation with Dr. Soni today — and find out what has been working against you.